NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Cannot have received: chemotherapy

Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses.

Cannot have received: radiation therapy

Has received radiotherapy for pancreatic cancer.

Cannot have received: anti-PD-1 therapy

Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.

Cannot have received: investigational agent

Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study.